argenx: all 93 studies

Page 1 of 1. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré SyndromeNot yet recruitingNCT07821762Phase 2
• A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNot yet recruitingNCT07773727Phase 2
• A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingNCT07760818Phase 2
• A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)Not yet recruitingNCT07746089Phase 3
• ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisRecruitingNCT07673627Phase 2
• A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult ParticipantsRecruitingNCT07673601Phase 1
• A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating PolyradiculoneuropathyNot yet recruitingNCT07638566Phase 2/3
• A Study Testing the Safety and Effects of FB102 in Healthy VolunteersRecruitingNCT07623057Phase 1
• A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsRecruitingNCT07612020Phase 1
• A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor NeuropathyRecruitingNCT07610564Phase 1
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingNCT07596849Phase 3
• A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in ItalyRecruitingNCT07595653
• A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsNot yet recruitingNCT07583641Phase 2
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingNCT07570316Phase 3
• A Study to Assess the Safety of ARGX-124 in Healthy VolunteersRecruitingNCT07377396Phase 1
• ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia GravisRecruitingNCT07294170
• A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular AtrophyRecruitingNCT07287982Phase 2
• ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodRecruitingNCT07284420Phase 2
• Real-World Efgartigimod Effectiveness in CIDP: A Prospective StudyRecruitingNCT07264426
• A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.RecruitingNCT07205159Phase 1
• A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)RecruitingNCT07194850Phase 2/3
• A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPRecruitingNCT07091630Phase 3
• Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac DiseaseRecruitingNCT06982963Phase 2
• A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPRecruitingNCT06920004Phase 3
• A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingNCT06909214Phase 4
• A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental VitiligoRecruitingNCT06905873Phase 1
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaRecruitingNCT06544499Phase 3
• A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingNCT06392386Phase 2/3
• A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.RecruitingNCT06299748
• A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod AlfaRecruitingNCT06298565
• A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4RecruitingNCT06078553
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationNCT05979441Phase 3
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisEnrolling by invitationNCT05374590Phase 2/3
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisRecruitingNCT04833894Phase 2/3
• Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)AvailableNCT04777734
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's SyndromeCompletedNCT06203457Phase 2Results posted
• Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTSTerminatedNCT05918978Phase 2Results posted
• A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)CompletedNCT05817669Phase 2Results posted
• A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidTerminatedNCT05681481Phase 3Results posted
• Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSCompletedNCT05633407Phase 2Results posted
• A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidCompletedNCT05267600Phase 2/3Results posted
• A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyCompletedNCT05225675Phase 2Results posted
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia GravisCompletedNCT04980495Phase 3Results posted
• Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia GravisCompletedNCT04818671Phase 3Results posted
• Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisCompletedNCT04735432Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaCompletedNCT04687072Phase 3Results posted
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)TerminatedNCT04598477Phase 3Results posted
• A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)CompletedNCT04598451Phase 3Results posted
• A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)CompletedNCT04281472Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).CompletedNCT04188379Phase 3Results posted
• A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.CompletedNCT03770403Phase 3Results posted
• An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT03669588Phase 3Results posted
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessCompletedNCT02965573Phase 2Results posted
• A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult ParticipantsCompletedNCT07782775Phase 1
• A Study to Assess the Safety of ARGX-213 in Healthy VolunteersCompletedNCT06968338Phase 1
• A Study to Assess the Safety of ARGX-109 in Healthy VolunteersCompletedNCT06799416Phase 1
• A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyActive, not recruitingNCT06742190Phase 3
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeActive, not recruitingNCT06684847Phase 3
• A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisActive, not recruitingNCT06655155Phase 2
• A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SCCompletedNCT06637072Phase 4
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Phase 3
• A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)Active, not recruitingNCT06503731Phase 2
• A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT06441682Phase 2
• A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)Active, not recruitingNCT06436742Phase 1
• A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.TerminatedNCT06307626Phase 3
• A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseTerminatedNCT06307613Phase 3
• A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisActive, not recruitingNCT06284954Phase 2
• A Prospective Longitudinal Study in Adults With Multifocal Motor NeuropathyActive, not recruitingNCT05988073
• A Study to Test How Kidney Problems Influence the Blood Concentrations of EfgartigimodCompletedNCT05927415Phase 1
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionActive, not recruitingNCT05907096Phase 2
• A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy AdultsCompletedNCT05817435Phase 1
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)TerminatedNCT05810961Phase 2
• A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)CompletedNCT05810948Phase 2
• A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy ParticipantsCompletedNCT05670704Phase 1
• A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.CompletedNCT05523167Phase 2/3
• A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor NeuropathyActive, not recruitingNCT05405361Phase 2
• Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IVCompletedNCT05163834Phase 1
• Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 StudyTerminatedNCT04936113Phase 2
• A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaActive, not recruitingNCT04812925Phase 3
• A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy VolunteersCompletedNCT04564066Phase 1
• SAD and MAD Study With IV and SC Doses of ARGX-117CompletedNCT04532125Phase 1
• Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisCompletedNCT04504279Phase 2
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)Active, not recruitingNCT04280718Phase 2
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)WithdrawnNCT04274452Phase 3
• A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).CompletedNCT04225156Phase 3
• Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy SubjectsCompletedNCT04073589Phase 1
• IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy VolunteersCompletedNCT03457649Phase 1
• A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male SubjectsCompletedNCT03334084Phase 1
• A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With PemphigusCompletedNCT03334058Phase 2
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITPCompletedNCT03102593Phase 2
• A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)CompletedNCT02759250Phase 1
• A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.CompletedNCT02055066Phase 1

← argenx overview and focus areas